SEAGULL HEALTH
Your health,We care!
Its core advantages lie in comprehensive and potent efficacy, outstanding intracranial activity, broad anti-resistance coverage, superior safety profile, and high accessibility.
AuthenticGuaranteeFast DeliveryPrivacy Furmonertinib (a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI targeted therapy drug) has clinically significa···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 83
Furmonertinib, a third-generation EGFR-TKI targeted therapeutic agent, should be administered strictly under medical supervision. Particular attention···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 80
The standard dosage of furmonertinib is oral administration twice daily, 80 mg each time (specific medication use shall follow the doctor's instru···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 76
Furmonertinib is a third-generation targeted therapy drug targeting epidermal growth factor receptor (EGFR) gene mutations, primarily indicated for th···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 80
Furmonertinib is an oral targeted therapeutic agent indicated for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 81
Furmonertinib is primarily indicated for patients with non-small cell lung cancer (NSCLC) harboring specific mutations in the epidermal growth factor ···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 77
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
